Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07423299 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Single and Multiple Ascending Dose Study of MT-251
A Phase 1 study of Healthy Volunteers, sponsored by Mirador Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT07423299 is a Phase 1 study of Healthy Volunteers that is actively recruiting participants, run by Mirador Therapeutics. The registered enrollment target is 70 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07423299, a Phase 1 study of Healthy Volunteers, is actively recruiting participants, sponsored by Mirador Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants
Conditions Studied
Interventions
- DRUG MT-251
Study Locations (1)
California
- Mirador Clinical Department - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-01-23 |
| Est. Completion | 2027-03-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07423299
The ClinicalTrials.gov registry entry for NCT07423299 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (85% lower). The listed sponsor is Mirador Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which MT-251 is the first listed.
NCT07423299 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07423299 about?
NCT07423299 is a clinical study titled "A First-in-Human Single and Multiple Ascending Dose Study of MT-251". A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants
What is the current status of trial NCT07423299?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2026-01-23. Estimated completion is 2027-03-08.
What conditions does trial NCT07423299 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT07423299?
The interventions under investigation include: MT-251 (DRUG).
Who is sponsoring clinical trial NCT07423299?
This trial is sponsored by Mirador Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07423299 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.